Handling Sirolimus In Clinical Practice

Research Summary

A consensus review from the Spanish Society of Nephrology on how the mTOR inhibitor sirolimus (rapamycin) is managed in everyday transplant practice — which side effects matter, which are serious, and what the working group advised for each.

Who Or What Was Studied?

A review of published trial and registry data on sirolimus in transplant patients, not a new study. It draws on the phase III development trials and later conversion or calcineurin-inhibitor withdrawal studies, plus animal experiments, and closes each section with consensus recommendations from the nephrologists who wrote it.

What Did The Research Show?

• Sirolimus raises total cholesterol, LDL cholesterol and triglycerides in a dose- and level-dependent way; the group still judged the overall cardiovascular profile favourable, citing data on atheroma in mice, intimal hyperplasia, lower blood pressure after calcineurin-inhibitor withdrawal and less cardiac allograft vasculopathy.
• Haematological effects include lower haemoglobin — often microcytic and poorly responsive to iron — and, less often, thrombocytopenia and leucopenia, which were mostly mild or reversible with dose reduction or temporary withdrawal.
• Thrombotic microangiopathy was more frequent when sirolimus was combined with cyclosporine (about 5.6% at the 5 mg dose versus 1.6% with placebo in combined studies 301 and 302), yet sirolimus has also been used successfully after calcineurin-inhibitor-related haemolytic uraemic syndrome.
• Other commonly reported problems include limb oedema, proteinuria after conversion (especially when baseline proteinuria exceeds 1 g/day), fluid collections (lymphocele) and delayed wound healing, mouth ulcers, diarrhoea, and pneumonitis — a rare but recognised lung reaction that usually resolves after stopping the drug.
• Sirolimus is embryotoxic in rats (no teratogenesis described) and is contraindicated in pregnancy, and the group notes that mTOR inhibitors, unlike calcineurin inhibitors, do not appear to promote tumours and were associated with fewer post-transplant cancers in these analyses.

Limitations And Interpretation

• This is a 2006 expert consensus review of transplant data, not a randomised comparison; its recommendations rest largely on lower-level evidence and clinical experience.
• It concerns transplant patients taking immunosuppressive doses of sirolimus, not the lower doses studied for ageing, so the side-effect rates cannot be transferred to other dosing.
• Much of the long-term safety picture still lacked controlled data at the time, as the authors themselves state.